US 9765066
Selective HDAC1 and HDAC2 inhibitors
granted A61KA61K31/4045A61K31/4709
Quick answer
US patent 9765066 (Selective HDAC1 and HDAC2 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regenacy Pharmaceuticals, Inc.
- Grant date
- Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/4045, A61K31/4709, A61K31/496, A61K31/498